As a comprehensive industry service platform in the Asia-Pacific region that spans the entire medical device value chain—integrating product technology, service innovation, trade, academic exchange, and education and learning—this year’s exhibition is themed “CMEF go forward,” inviting industry partners to jointly witness the strides of China’s medical device sector.

Dier Biotech has ramped up its R&D investment to drive industrial upgrading through innovation, showcasing at this major event a suite of automated infectious‑disease diagnostic instruments and accompanying reagents—developed in-house—including bacterial morphological analysis, bacterial culture, identification, and in vitro antimicrobial susceptibility testing. Among these, the D2Mini bacterial identification and susceptibility‑testing system features enhanced interpretation modules, improved human–machine interaction, and more flexible data‑transfer capabilities. Compared with conventional semi‑automated systems, it boasts a smaller footprint, faster throughput, and greater flexibility in data transmission. The D2Mini’s innovative design reflects Dier Biotech’s meticulous efforts to refine and upgrade its existing product line, earning widespread acclaim from users and partners alike.

  The Smart MS fully automated mass spectrometry system, a cutting-edge technology for clinical microbial identification, drew numerous medical professionals and product distributors to visit and engage in discussions. Its highly specialized on-site demonstration made Dier Bio one of the most closely watched exhibits in the industry.

Through in‑person, in‑depth discussions and hands‑on demonstrations, Dier Biotech has deepened customers’ understanding of the Dier brand and its products, providing robust technical support to curb bacterial resistance and prevent the overuse of antibiotics, and striving to enable every hospital to leverage superior microbiological testing services for the betterment of human health.